European Journal of Cancer
Volume 37, Issue 14 , Pages 1781-1789 , September 2001

Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial

  • M van Agthoven

      Affiliations

    • Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-10-408-8555; fax: +31-10-408-9094
    • ,
  • E Vellenga

      Affiliations

    • University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
    • ,
  • W.E Fibbe

      Affiliations

    • Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    • ,
  • T Kingma

      Affiliations

    • University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
    • ,
  • C.A Uyl-de Groot

      Affiliations

    • Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands

Received 23 April 2001 ,Accepted 29 May 2001.

References 

  1. Philip T, Armitage JO, Spitzer G, et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1987;316:1493–1498
  2. Philip T, Guglielmi C, Hagenbeek A, et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995;333:1540–1545
  3. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation (a prospective, randomized trial). J. Clin. Oncol. 1995;13:1323–1327
  4. Demirer T, Bensinger WI, Buckner CD. Peripheral blood stem cell mobilization for high-dose chemotherapy. J. Hematother. 1999;8:103–113
  5. Kanteti R, Miller KB, McCann JC, et al.  Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease (a clinical and molecular analysis). Bone Marrow Transplant. 1999;24:473–481
  6. Schmitz N, Linch DC, Dreger P, et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–357
  7. Faucher C, le Corroller AG, Blaise D, Novakovitch G, Manonni P, Moatti JP, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation (clinical assessment and cost-effectiveness). Bone Marrow Transplant. 1994;14:895–901
  8. Ager S, Scott MA, Mahendra P, et al.  Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma (a retrospective comparison with autologous bone marrow transplantation). Bone Marrow Transplant. 1995;16:79–83
  9. Smith TJ, Hillner BE, Schmitz N, et al.  Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J. Clin. Oncol. 1997;15:5–10
  10. Woronoff-Lemsi MC, Arveux P, Limat S, Deconinck E, Morel P, Cahn JY. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant. 1997;20:975–982
  11. Uyl-de Groot CA, Richel DJ, Rutten FFH. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur. J. Cancer. 1994;30A:1631–1635
  12. Hartmann O, Le Corroller AG, Blaise D, et al.  Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas (hematologic recovery and costs. A randomized, controlled trial). Ann. Intern. Med. 1997;15:600–607
  13. Waters TM, Benett CL, Pajeau TS, et al.  Economic analyses of bone marrow transplantation and blood stem cell transplantation for leukemias and lymphoma (what do we know?). Bone Marrow Transplant. 1998;21:641–650
  14. Sweetenham JW. Economics of stem cell transplantation for lymphoma (counting the cost of the living). Br. J. Cancer. 2000;82:4–6
  15. Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma. Results in accelerated hematpoietic reconstitution, improved quality of life and cost reduction in comparison with bone marrow transplantation: the HOVON-22 study. Br J Haematol 2001, in press.
  16. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, Oxford: Oxford University Press; 1997;
  17. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for Costing Research. Amstelveen, Health Care Board, 2000 (in Dutch).
  18. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, Oxford: Oxford University Press; 1996;
  19. In:  van der Kuy A editors. Pharmacotherapeutical Compass. Amstelveen: Health Care Board; 1997;
  20. Uyl-de Groot CA, Rutten FFH, Bonsel GJ. Measurement and valuation of quality of life in economic appraisal of cancer treatment. Eur. J. Cancer. 1994;30A:111–117
  21. Dolan P. Modeling valuations for the EuroQol health states. Med. Care. 1997;35:1095–1108
  22. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales (A User's Manual). Boston, MA: The Health Institute, New England Medical Center; 1994;
  23. de Haes JCJM, Olschewski M, Fayers P, et al.  Measuring the Quality of Life of Cancer Patients with the Rotterdam Symptom Checklist (A Manual). Groningen: Northern Centre for Healthcare Research; 1996;
  24. van de Zee KI, Sanderman R. Measuring the General Health State with the RAND-36: A Manual. Groningen, Northern Centre for Healthcare Research, 1993 (in Dutch).
  25. Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM, Fields KK. Quality of life following bone marrow transplantation for breast cancer (a comparative study). Bone Marrow Transplant. 1997;19:257–264
  26. Clark JA, Rieker P, Joy Propert K, Talcott JA. Changes in quality of life following treatment for early prostate cancer. Urology. 1999;53:161–168
  27. Rogers SN, Humphris G, Lowe D, Brown JS, Vaughan ED. The impact of surgery for oral cancer on quality of life as measured by the Medical Outcomes Short Form 36. Oral Oncol. 1998;34:171–179
  28. Funk GF, Hynds Karnell L, Dawson CJ, et al.  Baseline and post-treatment assessment of the general health status of head and neck cancer patients compared with United States population norms. Head Neck. 1997;19:675–683
  29. Schulman K, Burke J, Drummond M, et al.  Resource costing for multinational neurologic clinical trials (methods and results). Health Econ. 1998;7:629–638
  30. Uyl-de Groot CA, Huijgens PC, Rutten FFH. Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs. Pharmacoeconomics. 1996;10:23–35

PII: S0959-8049(01)00198-8

European Journal of Cancer
Volume 37, Issue 14 , Pages 1781-1789 , September 2001

Article Tools

* Image Usage & Resolution